127 related articles for article (PubMed ID: 38875295)
41. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
42. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
[TBL] [Abstract][Full Text] [Related]
43. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
44. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma.
Showpnil IA; Selich-Anderson J; Taslim C; Boone MA; Crow JC; Theisen ER; Lessnick SL
Nucleic Acids Res; 2022 Sep; 50(17):9814-9837. PubMed ID: 36124657
[TBL] [Abstract][Full Text] [Related]
45. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
46. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
[TBL] [Abstract][Full Text] [Related]
47. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
48. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
Yuan B; Ji W; Xia H; Li J
Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
[TBL] [Abstract][Full Text] [Related]
49. EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
Yasir M; Park J; Chun W
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894854
[TBL] [Abstract][Full Text] [Related]
50. A Druggable Rheostat for Ewing Sarcoma?
Weiss KR; Bailey KM
Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
[TBL] [Abstract][Full Text] [Related]
51. Genetically Engineered Mouse Model in Ewing Sarcoma.
Tanaka M; Nakamura T
Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102
[TBL] [Abstract][Full Text] [Related]
52. The Promoter-Associated Noncoding RNA
Palombo R; Frisone P; Fidaleo M; Mercatelli N; Sette C; Paronetto MP
Cancer Res; 2019 Jul; 79(14):3570-3582. PubMed ID: 31072811
[TBL] [Abstract][Full Text] [Related]
53. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
[TBL] [Abstract][Full Text] [Related]
54. Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles.
Tsugita M; Yamada N; Noguchi S; Yamada K; Moritake H; Shimizu K; Akao Y; Ohno T
PLoS One; 2013; 8(10):e77416. PubMed ID: 24124617
[TBL] [Abstract][Full Text] [Related]
55. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD
Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901
[TBL] [Abstract][Full Text] [Related]
56. SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.
Su S; Chen J; Jiang Y; Wang Y; Vital T; Zhang J; Laggner C; Nguyen KT; Zhu Z; Prevatte AW; Barker NK; Herring LE; Davis IJ; Liu P
Adv Sci (Weinh); 2021 Jul; 8(14):e2004846. PubMed ID: 34060252
[TBL] [Abstract][Full Text] [Related]
57. Phosphoproteomic profiling reveals IL6-mediated paracrine signaling within the Ewing sarcoma family of tumors.
Anderson JL; Titz B; Akiyama R; Komisopoulou E; Park A; Tap WD; Graeber TG; Denny CT
Mol Cancer Res; 2014 Dec; 12(12):1740-54. PubMed ID: 25092916
[TBL] [Abstract][Full Text] [Related]
58. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
59. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
60. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]